Predictive Toxicity Test Linked to Radiotherapy After Mastectomy and Immediate Implant Reconstruction (PRETORIA)

  • End date
    Jun 5, 2027
  • participants needed
  • sponsor
    Institut du Cancer de Montpellier - Val d'Aurelle
Updated on 5 July 2022
adjuvant chemotherapy
breast reconstruction


This study evaluates the capacity of the NovaGray RILA Breast® test to predict the toxicity linked to radiotherapy and the impact of implant breast reconstruction.


Immediate reconstruction after mastectomy may help women with breast cancer to deal with their fear of mastectomy, spare them one or more second surgery and additional hospital stays in case of late breast reconstruction. However, in France, most patients with invasive breast carcinoma and treated with mastectomy are not offered immediate reconstruction. One reason is the need for postoperative radiotherapy for most patients (40 to 70% according to the centers). Indeed, radiotherapy induces side-effects which can alter the cosmetic result of the breast reconstruction as well as the patient's quality of life. Since 1995, a significant correlation is observed between the RILA test (measurement by flux cytometry of the lymphocyte T-CD8 apoptosis induced by radiotherapy) and the risk of occurrence of severe radio-induced breast fibrosis. Such accurate personalized medical care could allow identifying before any treatment high risk of toxicity patients and thus help establishing the therapeutic strategy. Identification of low-risk patients could also allow limiting autologous samplings and thus their associated morbidity.

Condition Breast Cancer, Capsular Contracture Associated With Breast Implant
Treatment NovaGray RILA Breast® test
Clinical Study IdentifierNCT04342546
SponsorInstitut du Cancer de Montpellier - Val d'Aurelle
Last Modified on5 July 2022


Yes No Not Sure

Inclusion Criteria

Age ≥18 years
Patients with histologically confirmed breast cancer with indication of mastectomy or surgery with mastectomy performed
Indication of wall chest radiation after mastectomy
Patient's agreement to receive or having had an immediate breast reconstruction by implant in one or two steps, with or without a dermal or synthetic matrix (depending on the habits of the center)
Performance Status 0-1
Consent signed before any study procedure
Patient geographically accessible for follow-up
Affiliated to the French national social security system

Exclusion Criteria

Breast reconstruction with flap
Inflammatory breast cancer (cT4d)
Skin or parietal breast cancer (cT4 a, b or c)
Metastatic patients
Patients with bilateral breast cancer
History of homolateral breast cancer treated with radiotherapy
History of contralateral breast cancer
Pregnant or breastfeeding women or women of childbearing potential unwilling to employ adequate contraception
Legal incapacity or physical, psychological or mental status interfering with the patient's ability to sign the informed consent
Participation in an interventional clinical study or planned participation during study up to 12 months post-radiotherapy
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact


Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note